The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
January 18, 2019
We are currently experiencing a temporary delay in printing and mailing the hard copy of your license. Please click here for more information. Continue reading
January 11, 2019
The Annual Long Range Planning meeting has been scheduled for Friday, May 31, 2019. Please click here for more information. Continue reading